Journal of the American Academy of Dermatology
Volume 60, Issue 6 , Pages 1037-1041 , June 2009

Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin

  • Jeanmarie B. Rey, BA
    • ,
  • Rebecca B. Luria, MD

      Affiliations

    • Corresponding Author InformationCorrespondence to: Rebecca B. Luria, MD, Department of Dermatology C1078, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814.

References 

  1. Heymann WR. Scleromyxedema. J Am Acad Dermatol. 2007;57:890–891
  2. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol. 1995;33:37–43
  3. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273–281
  4. Wojas-Pelc A, Blaszczyk M, Glinska M, Jablonska S. Tumorous variant of scleromyxedema: successful therapy with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2005;19:462–465
  5. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore). 2008;87:10–20
  6. Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28:105–108
  7. Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289–294
  8. Gholam P, Hartman M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol. 2007;157:1040–1085
  9. Shergill B, Orteu CH, McBride SR, Rustin MH. Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin. Br J Dermatol. 2005;153:650–652
  10. Rodrigues M, Machado A, Ventura F, Duarte ML, Ferreira C. Scleromyxedema diagnosis following unexplained encephalopathy. Eur J Dermatol. 2008;18:78–79
  11. Lister RK, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol. 2000;43:403–408
  12. Gonzalez J, Palangio M, Schwartz J, Klainer AS, Bisaccia E. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol. 2000;42:927–928
  13. River Y, Levy I, Gilead L, Orbach H, Almog Y. Fever, convulsions and coma in scleromyxedema: a “dermato-neuro syndrome.”. Neurology. 1996;46:1778–1779
  14. Harper R, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science. 1978;199:545–547
  15. Kulczycki A, Nelson M, Eisen A, Heffernan M. Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. Br J Dermatol. 2003;149:1276–1281
  16. Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol. 1999;40:303–307
  17. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001;137:1071–1072
  18. Iranzo P, Lopez-Lerma I, Blade J, Rovira M, Herrero C. Scleromyxoedema treated with autologous stem cell transplantation. J Eur Acad Dermatol Venereol. 2007;21:129–130
  19. Illa I, de la Torre C, Rojas-Garcia R, Altes A, Blesa R, Sierra J, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood. 2006;108:773–774
  20. Rosenbach M, Werth VP. Dermatologic therapeutics: thalidomide; a practical guide. Dermatol Ther. 2007;20:175–186
  21. Amini-Adle M, Thieulent N, Dalle S, Balme B, Thomas L. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology. 2007;214:58–60
  22. Thyssen JP, Zachariae C, Menne T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol. 2006;20:1396–1397
  23. Jacob SE, Fien S, Kerdel FA. Scleromyxedema, a positive effect with thalidomide. Dermatology. 2006;213:150–152
  24. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol. 2004;140:277–280
  25. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol. 2004;51:126–131
  26. Horn KB, Horn MA, Swan J, Singhal S, Guitart J. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004;51(Suppl):S120–S123
  27. Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol. 2005;53:739–740
  28. Craig NM, Putterman AM, Roenigk RK, Wang TD, Roenigk HH. Multiple periorbital cutaneous myxomas progressing to scleromyxedema. J Am Acad Dermatol. 1996;34:928–930
  29. Keong CH, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, Iino Y, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol. 1990;22:842–844
  30. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum. 2008;38:188–194
  31. Wetter DA, Davis MDP, Yiannias JA, Gibson LE, Dahl MV, El-Azhary RA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc. 2005;80:41–47
  32. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol. 2006;6:523–527
  33. Hamrock D. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6:535–542
  34. Righi A, Schiavon F, Doria A, Blasczyk M, Rondinone R, Todesco S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis. 2002;61:59–61
  35. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10:85–86
  36. Topf S, Simon M, Schell H, Luftl M. Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin [German]. Hautarzt. 2007;58:525–528
  37. Korber A, Franckson T, Grabbe S, Dissemond J. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol. 2007;21:553–554
  38. Karim A, Lawlor F, Black MM. Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin. Clin Exp Dermatol. 2004;29:317–318
  39. Lai AF, Suurmond D, Radl J, van Furth R. Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein IgG of type kappa. Br J Dermatol. 1973;88:107–109
  40. Farmer ER, Hambrick GW, Shulman LE. Papular mucinosis: a clinicopathologic study of four patients. Arch Dermatol. 1982;118:9–13
  41. Kantor GR, Bergfeld WF, Katzin WE, Reynolds OD, Biscardi AP, Lobur DM, et al. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol. 1986;14:879–888
  42. Verier A, Jouet JP, Muller JP, Destee A, Thomas P, Warot P. Papular mucinosis, recurrent comas, and benign dysglobulinemia. Rev Neurol (Paris). 1987;143:791–797
  43. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol. 1988;19:469–477
  44. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat JH, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142:213–217
  45. Smith DI, Swamy PM, Heffernan MP. Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2). J Am Acad Dermatol. 2007;56:e1–54
  46. Kaveri S, Bayary J, Dasgupta S, Misra N, Ephrem A, Duong Van Huyen JP, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol. 2006;6:528–534
  47. Molina V, Haj-Yahia S, Solodeev I, Levy Y, Blank M, Shoenfeld Y. Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG). Autoimmunity. 2006;39:711–717
  48. Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29:321–326

 The opinions or assertions contained herein are the private view of the authors and are not to be construed as official or as reflecting the views of the US Army, US Navy, US Air Force, or the Department of Defense.

 Funding sources: None.

 Conflicts of interest: None declared.

 Reprints not available from the authors.

PII: S0190-9622(08)01442-4

doi: 10.1016/j.jaad.2008.11.013

Journal of the American Academy of Dermatology
Volume 60, Issue 6 , Pages 1037-1041 , June 2009

Article Tools

* Image Usage & Resolution